Quimpharma has completed the divestiture of a product portfolio to Megalabs

April 2026 — Quimpharma has completed the divestiture of a product portfolio to Megalabs México.

Quimpharma is a Mexican pharmaceutical company focused on the development, manufacture and distribution of prescription, over-the-counter (OTC), food supplement and dermocosmetic products. With over 22 years of history, the company has established a strong position in the Mexican market, supported by a robust R&D division and a portfolio of more than 40 products across key therapeutic categories. The company operates a manufacturing facility with liquid and solid production lines, a distribution center and corporate offices in Mexico City, enabling nationwide reach and consistent product availability.

Megalabs México, through Italmex, is part of Megalabs, a Uruguay-based pharmaceutical group with a strong presence across Latin America. The company develops and commercializes innovative, high-quality pharmaceutical products, dermocosmetics and nutritional supplements across multiple therapeutic areas, working closely with healthcare professionals to support patients’ health and wellbeing throughout Mexico and the region.

Our role in the transaction

Oaklins’ team in Mexico acted as the exclusive sell-side advisor to Quimpharma in the divestiture of a product portfolio to Megalabs. This transaction highlights Oaklins’ expertise in the healthcare sector and reinforces its strong track record advising mid-market companies through complex, cross-border processes.